Advanced CellTechnology Announces Upcoming Milestones at BIO Europe 2009

IND Filing for RPE Program Expected by 2009 Year-end; Company Announces Plans to
File IND For Second Clinical Program During First Half of 2010
WORCESTER, Mass.--(Business Wire)--
Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTCBB: ACTC) announced
today that its Chief Executive Officer, William Caldwell, IV, presented at the
BIO Europe Conference being held in Vienna, Austria. The presentation provided a
corporate overview and update on the Company`s plans for its clinical pathway in
addition to several other upcoming developmental milestones, including its
planned IND filing with the FDA for its retinal pigment epithelial (RPE) program
prior to the end of this year, and its goal of becoming one of the first
companies to treat a patient with an embryonic stem cell based therapy, which it
hopes to achieve by the third quarter of 2010. Pending FDA approval, ACT hopes
to commence Phase I clinical trials for its first IND designation in the summer
of 2010, and anticipates filing an IND for an additional retinal indication in a
similar timeframe.

"We are extremely pleased to have the opportunity to announce exciting upcoming
corporate developments at such a prestigious gathering of Europe`s finest
biotech organizations," remarked William Caldwell, CEO of ACT. "We expect that
this presentation will serve to greatly enhance our visibility within the
international biotech community and could lead to further interest from
potential strategic partners who would be interested in working with us in
further developing our portfolio of potentially revolutionary regenerative
therapies."

BIO-Europe is Europe's largest partnering conference, serving the global
biotechnology industry. The conference annually attracts top executives from the
biotechnology, pharmaceutical and finance industries, along with the most
exciting emerging companies. Produced with the support of BIO, it is regarded as
a "must attend" event for the biotech industry.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future ability to draw on the credit
Facility, future financial and operating results, future growth in research and
development programs, potential applications of our technology, opportunities
for the Company and any other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Any statements that are not statements of historical fact (including
statements containing the words "will," "believes," "plans," "anticipates,"
"expects," "estimates," and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by such
forward-looking statements, including: limited operating history, need for
future capital, risks inherent in the development and commercialization of
potential products, protection of its intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect the Company`s results and other risks and uncertainties are detailed from
time to time in the company`s periodic reports, including the report on Form
10-K for the year ended December 31, 2008. Forward-looking statements are based
on the beliefs, opinions, and expectations of the company`s management at the
time they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change.

CEOcast, Inc. for Advanced Cell
Dan Schustack, 212-732-4300

Copyright Business Wire 2009